Caris Life Sciences, Inc. Common Stock (CAI) Stock Price
CAIStock
$30.56−4.35%52W
Market Cap$8.64B
P/E—
PEG Ratio—
Div yield—
Beta0.40
CAI Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)41.46%
Price vs S&P 500 (4W)1.03%
VGM Score60.49
CAI Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | $0.01 | $0.00 | -100.00%(-$0.01) | |
| Q1 2026 | -$0.02 | $0.00 | +100.00%(+$0.02) | |
| Q4 2025 | $0.10 | $0.28 | +168.69%(+$0.18) | |
| Q3 2025 | -$0.14 | $0.08 | +158.83%(+$0.22) | |
| Q2 2025 | -$0.22 | -$1.11 | -411.18%(-$0.89) |
CAI Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.31
4.19
4.13
4.13
Industry Peers — Health Services(30)
| Symbol | Value Score | Growth Score | Momentum Score | P/E Ratio (Annual) | Revenue Growth TTM (YoY) | Operating Margin (TTM) | ROE (TTM) | Price |
|---|---|---|---|---|---|---|---|---|
CAICaris Life Sciences, Inc. Common Stock | F | A | B | — | 38.5% | 12.7% | 18.8% | $30.56 |
| NTRANatera, Inc. Common Stock | F | A | A | — | 37.8% | -10.7% | -11.7% | $393.44 |
| DGXQuest Diagnostics Inc. | C | D | B | 26.1x | 9.9% | 14.1% | 14.5% | $235.00 |
| LHLabcorp Holdings Inc. | C | D | B | 29.4x | 6.4% | 10.4% | 11.6% | $317.95 |
| GHGuardant Health, Inc. Common Stock | F | A | B | — | 42.7% | -40.2% | -246.6% | $158.60 |
| RDNTRadNet, Inc. Common Stock | D | C | C | 1779.3x | 18.9% | 3.0% | -1.9% | $68.80 |
| GRALGRAIL, Inc. Common Stock | D | B | B | — | 23.1% | -338.4% | -15.9% | $117.81 |
| BLLNBillionToOne, Inc. Class A Common Stock | F | F | C | 621.1x | — | 10.9% | 8.9% | $98.12 |
| VCYTVeracyte, Inc. | D | B | C | 52.2x | 17.3% | 19.6% | 8.6% | $43.12 |
| CDNACareDx, Inc. | D | B | A | 18.3x | 34.4% | 23.6% | 32.8% | $64.00 |
| CELCCelcuity Inc. Common Stock | — | — | D | — | — | — | -244.6% | $56.58 |
About Caris Life Sciences, Inc. Common Stock
Caris Life Sciences develops AI-powered molecular diagnostic solutions for oncology, enabling personalized cancer treatment decisions. The company leverages comprehensive molecular profiling and machine learning algorithms to provide physicians with precision medicine insights. Its technology platform aims to improve patient outcomes while supporting clinical and pharmaceutical decision-making.